InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901.
The data showed a favorable bioavailability profile of the INM-901 oral formulation, supporting its potential utility in neurodegenerative disorders like Alzheimer's disease.
Neurological assessments revealed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile.
Robust Bioavailability
INM-901 demonstrated robust bioavailability in in vivo models, achieving therapeutic systemic exposure levels.
Support for Clinical Trials
The data will support the design and planning of the first in human clinical trials for INM-901.
Neurological Safety
Neurological assessments showed no adverse effects, bolstering confidence in the compound's safety profile.
- The successful completion of the PK studies in large animals sets a strong foundation for InMed's INM-901 program.
- The favorable bioavailability and safety profile of INM-901 provide promising prospects for its advancement towards human clinical trials and potential therapeutic applications.
InMed's advancements in the PK studies for INM-901 demonstrate promising results, paving the way for future developments in the treatment of Alzheimer's disease.